Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Jetstar to Charge for Overhead Cabin Bags From February 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time.
NEW YORK, March 13, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Monday, March 19, 2018.
| Conference Call & Webcast | ||||||
| Monday, March 19th @ 4:30pm Eastern Time | ||||||
| Domestic: | 800-289-0438 | |||||
| International: | 323-994-2083 | |||||
| Passcode: | 1979356 | |||||
| Webcast: | http://public.viavid.com/index.php?id=128779 | |||||
| Replays available through April 2: | ||||||
| Domestic: | 844-512-2921 | |||||
| International: | 412-317-6671 | |||||
| Conference ID: | 1979356 | |||||
| | ||||||
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
